Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MARQUEE
- Sponsors ArQule; Daiichi Sankyo Inc
- 27 Dec 2017 Results of exploratory subgroup analysis assessing efficacy and safety, published in the Journal of Thoracic Oncology.
- 28 Oct 2016 This trial was completed in Denmark (end date: 2016-10-06), according to European Clinical Trials Database.
- 20 Oct 2016 This trial was completed in Germany (end date: 2016-10-06), according to European Clinical Trials Database.